BioMarin CFO awarded new performance stock grants

BioMarin Pharmaceutical executive Brian Mueller received multiple performance-based stock awards.

Rhea-AI Filing Summary

BioMarin Pharmaceutical executive Brian Mueller received multiple performance-based stock awards. On February 25, 2026, he acquired 6,683, 7,230, and 2,569 shares of common stock at $0 per share through grants classified as awards, not open-market purchases.

These shares come from Restricted Stock Units earned for performance over 2023–2025, based on relative total shareholder return, development goals, and core operating margin. The earned RSUs convert into common stock on a 1:1 basis and are scheduled to vest on March 15, 2026, subject to his continued service, with earlier vesting possible upon certain events. Following these awards, he directly owns 116,638 common shares.

Insider Trade Summary

Grant/Award: 16,482 shares

Grant/Award 3 txns

Insider Mueller Brian

Role EVP, Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	6,683	$0.00	$0.00
Grant/Award	Common Stock	7,230	$0.00	$0.00
Grant/Award	Common Stock	2,569	$0.00	$0.00

Holdings After Transaction: Common Stock — 116,638 shares (Direct)

Footnotes (5)

1. F1. Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis.
2. F2. Represents the total number of RSUs earned pursuant to a formula based on relative total shareholder return during 2023 through 2025 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan.
3. F3. Although earned, the RSUs only vest according to the following schedule: vests on March 15, 2026, subject to the reporting person's continued service through that date, subject to earlier vesting upon certain events.
4. F4. Represents the total number of RSUs earned pursuant to a formula based on the number and nature of development goals achieved during 2023 through 2025 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan.
5. F5. Represents the total number of RSUs earned pursuant to a formula based on core operating margin over three, one-year periods spanning 2023 through 2025 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan.

FAQ

What did BioMarin (BMRN) CFO Brian Mueller report in this insider filing?

Brian Mueller reported stock awards, not open-market trades. He acquired several blocks of BioMarin common stock through performance-based RSU grants that converted 1:1 into shares after being earned for results over 2023–2025.

How many BioMarin shares did the CFO receive through these RSU awards?

The CFO received separate grants of 6,683, 7,230, and 2,569 BioMarin common shares. Each block reflects performance-based RSUs that were earned and then converted into shares at no cash cost per share to him.

What performance periods and metrics determined Brian Mueller’s BioMarin RSU awards?

The RSUs were earned over 2023–2025. Formulas used relative total shareholder return, achievement of specified development goals, and core operating margin across three one-year periods to determine how many performance-based RSUs converted into common shares.

When do Brian Mueller’s newly earned BioMarin RSUs vest?

Although the RSUs are earned, they vest on March 15, 2026. Vesting requires Brian Mueller’s continued service through that date, with the potential for earlier vesting if certain specified events occur under the company’s equity plan.

How many BioMarin common shares does the CFO own after these grants?

After the latest grant reported, Brian Mueller directly owns 116,638 BioMarin common shares. This figure reflects his updated direct holdings following the conversion of earned performance-based RSUs into common stock at a one-for-one ratio.

Were these BioMarin stock transactions open-market buys or compensation awards?

These transactions are compensation awards, not open-market purchases. They are classified as grants or other acquisitions, with a transaction price of $0 per share, reflecting performance-based RSUs converting into common stock under the 2017 Equity Incentive Plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/26/2026 - 08:28 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mueller Brian

(Last) (First) (Middle)

C/O BIOMARIN PHARMACEUTICAL INC.

770 LINDARO STREET

(Street)

SAN RAFAEL CA 94901

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIOMARIN PHARMACEUTICAL INC [ BMRN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/25/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/25/2026(1)		A		6,683(2)(3)	A	$0	106,839	D
Common Stock	02/25/2026(1)		A		7,230(3)(4)	A	$0	114,069	D
Common Stock	02/25/2026(1)		A		2,569(3)(5)	A	$0	116,638	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis.

2. Represents the total number of RSUs earned pursuant to a formula based on relative total shareholder return during 2023 through 2025 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan.

3. Although earned, the RSUs only vest according to the following schedule: vests on March 15, 2026, subject to the reporting person's continued service through that date, subject to earlier vesting upon certain events.

4. Represents the total number of RSUs earned pursuant to a formula based on the number and nature of development goals achieved during 2023 through 2025 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan.

5. Represents the total number of RSUs earned pursuant to a formula based on core operating margin over three, one-year periods spanning 2023 through 2025 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan.

Remarks:

	/s/ Tae Sang Yoo, Attorney-in-Fact	02/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.